



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 9th July, 2018

To,
Mr. Kautak Upadhyay,
Manager,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No.C-1, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

**Sub: - Discrepancy in the Audited Financial Results provided by the
Company as per Regulation 33 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015**

Ref: NSE/LIST/FR/7152 dated 03.07.2018

Dear Sir,

With reference to the captioned subject, due to some inadvertence, we missed to submit the Standalone and Consolidated Reconciliation of Equity of Audited Financial Results with the quick results. Please find attached herewith the Standalone and Consolidated Reconciliation of Equity of Audited Financial Results duly signed by Shri Vinod Kumar Gupta (DIN: 00039145), Managing Director of the Company.

Kindly consider the same and take the same on record as a submission of the Audited Financial Results.

Thanking You

For Parenteral Drugs (India) Limited


Company Secretary

Attached: A/a





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

A reconciliation between the Equity as reported under previous GAAP and the Ind AS for the year ended March 31, 2017 and 1st April, 2016 is given below:

Standalone Reconciliation of the Total Equity as on 31st March 2017 and 1st April 2016

Description	(Rs. In Lakhs)	
	31st March 2017	1st April 2016
Total Equity as per previous GAAP (Indian GAAP)	17,611.55	28942.14
Impairment loss on of investment in subsidiaries	(13,600.00)	(13600.00)
Provisions for receivable on Expected credit loss model	(1,251.46)	(1524.57)
Fair valuation on account of invetsment in Preference shares	(4.75)	(14.24)
Employee Benefits Expenses	87.56	0.00
Deferred tax impact on above	3,524.49	3608.88
Liability Portion of Preference Share transferred to Borrowing	(7,488.56)	(7123.16)
Deferred Government Grant transfer to Other non Current Liability	(30.00)	(30.00)
Deferred Government Grant consider as Income	10.50	9.00
Other comprehensive income (net of tax expenses)	(25.39)	5.11
Total Adjustment	(18,777.61)	(18,668.98)
Total Equity as per Ind AS	(1,166.06)	10,273.16

For & on behalf of the Board of Directors

Place: Indore

Date: 29-06-2018

Vinod Kumar Gupta
Managing Director
DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M5080912IF

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

A reconciliation between the Equity as reported under previous GAAP and the Ind AS for the year ended March 31, 2017 and 1st April, 2016 is given below:

Consolidated Reconciliation of the Total Equity as on 31st March 2017 and 1st April 2016

(Rs. In Lakhs)		
Description	31st March 2017	1st April 2016
Total Equity as per previous GAAP (Indian GAAP)	21,027.74	32537.96
Impairment of Goodwill	762.41	762.41
Impairment loss on of investment in subsidiaries	(13,600.00)	(13600.00)
Minority Interest	0.37	0.37
Provisions for receivable on Expected credit loss model	(1,268.69)	(1564.39)
Fair valuation on account of invetsment in Preference shares	(5.41)	(14.90)
Employee Benefits Expenses	71.60	0.00
Deferred tax impact on above	3,547.34	3621.48
Liability Portion of Preference Share transferred to Borrowing	(12,252.10)	(11685.31)
capital reserve due to Subsidiary	17.27	17.27
Deferred Government Grant transfer to Other non Current Liability	(30.00)	(30.00)
Deferred Government Grant consider as Income	10.50	9.00
Other comprehensive income (net of tax expenses)	(25.39)	5.11
Total Adjustment	(22,772.10)	(22,478.96)
Total Equity as per Ind AS	(1,744.36)	10,059.00

Place: Indore
Date: 29-06-2018

For & on behalf of the Board of Director:

Vinod Kumar Gupta
Managing Director
DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register